Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1793-1797

  Tada, Mitsuhiro ^a   Matsumoto, Ryoji ^a   Iggo, Richard D ^b   Onimaru, Rikiya ^a   Shirato, Hiroki ^a   Sawamura, Yutaka ^a   Shinohe, Yumiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CHILD; CLINICAL ARTICLE; CLINICAL PATHWAY; FEMALE; GENE DELETION; GENETIC TRANSDUCTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; JAPAN; MALE; OUTCOMES RESEARCH; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; SUPPRESSOR GENE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GENES, P53; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032080417     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 Status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
2. Symonds, H., Krall, L., Remington, L., Saenz Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703-711, 1994.
3. Klijn, J. G. M. Prognostic and Predictive Value of p53, pp. 1-163, Amsterdam: Elsevier Science, 1997.
4. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
5. Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., and Sherr, C. J. Tumor suppression at the mouse ink4a locus mediated by the alternative reading frame product p19(arf). Cell, 91: 649-659, 1997.
6. Garkavtsev, I., Grigorian, I. A., Ossovskaya, V. S., Chernov, M. V., Chumakov, P. M., and Gudkov, A. V. The candidate tumour suppressor p33(ing1) cooperates with p53 in cell growth control. Nature (Lond.), 391: 295-298, 1998.
7. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
8. Barak, Y., Juven, T., Haffner, R., and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J., 12: 461-468, 1993.
9. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell, 80: 293-299, 1995.
10. Reed, J. C. Double identity for proteins of the Bcl-2 family. Nature (Lond.), 387: 773-776, 1997.
11. Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavenee, W., and Vogelstein, B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature (Lond.), 355: 846-847, 1992.
12. Tada, M., Iggo, R. D., Ishii, N., Shinohe, Y., Sakuma, S., Estreicher, A., Sawamura, Y., and Abe, H. Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int. J. Cancer, 67: 447-450, 1996.
13. von Deimling, A., von Ammon, K., Schoenfeld, D., Wiestler, O. D., Seizinger, B. R., and Louis, D. N. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol., 3: 19-26, 1993.
14. Tada, M., Iggo, R. D., Waridel, F., Nozaki, M., Matsumoto, R., Sawamura, Y., Shinohe, Y., Ikeda, J., and Abe, H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol. Carcinog., 18: 171-176, 1997.
15. Ellison, D. W., Steart, P. V., Bateman, A. C., Pickering, R. M., Palmer, J. D., and Weller, R. O. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J. Neurol. Neurosurg. Psychiatry, 59: 413-419, 1995.
16. Rasheed, B. K., McLendon, R. E., Herndon, J. E., Friedman, H. S., Friedman, A. H., Bigner, D. D., and Bigner, S. H. Alterations of the TP53 gene in human gliomas. Cancer Res., 54: 1324-1330, 1994.
17. Soini, Y., Niemela, A., Kamel, D., Herva, R., Bloigu, R., Paakko, P., and Vahakangas, K. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS, 102: 786-792, 1994.
18. Iuzzolino, P., Ghimenton, C., Nicolalo, A., Giorgiutti, F., Fina, P., Doglioni, C., and Barbareschi, M. p53 protein in low-grade astrocytomas: a study with long-term follow-up. Br. J. Cancer, 69: 586-591, 1994.
19. Chozick, B. S., Pezullo, J. C., Epstein, M. H., and Finch, P. W. Prognostic implications of p53 overexpression in supratentrial astrocytic tumors. Neurosurgery (Baltimore), 35: 831-838, 1994.
20. Pollack, I. F., Hamilton, R. L., Finkelstein, S. D., Campbell, J. W., Martinez, A. J., Sherwin, R. N., Bozik, M. E., and Gollin, S. M. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res., 57: 304-309, 1997.
21. Simpson, J. R., Horton, J., Scott, G., Curran, W. J., Rubin, P., Fischbach, J., Isaacson, S., Rotman, M., Asbell, S. O., Nelson, J. S., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys., 26: 239-244, 1993.
22. Kreth, F. W., Warnke, P. C., Scheremet, R., and Ostertag, C. B. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J. Neurosurg., 78: 762-766, 1993.
23. Jeremic, B., Grujicic, D., Antunovic, V., Djuric, L., Stojanovic, M., and Shibamoto, Y. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J. Neurooncol., 21: 177-185, 1994.
24. Obwegeser, A., Ortler, M., Seiwald, M., Ulmer, H., and Kostron, H. Therapy of glioblastoma multiforme: a cumulative experience of 10 years. Acta Neurochir. (Wien), 137: 29-33, 1995.
25. Barker, F. G., II, Prados, M. D., Chang, S. M., Gutin, P. H., Lamborn, K. R., Larson, D. A., Malec, M. K., McDermott, M. W., Sneed, P. K., Wara, W. M., and Wilson, C. B. Radiation response and survival time in patients with glioblastoma multiforme. J. Neurosurg., 84: 442-448, 1996.
26. Kleihues, P., Burger, P. C., and Scheithauer, B. W. Histological Typing of Tumours of the Central Nervous System. Berlin: Springer-Verlag, 1993.
27. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
28. Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., and Skinner, D. G. p53 and treatment of bladder cancer. Nature (Lond.), 385: 123-125, 1997.
29. Flaman, J-M., Frebourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P., Sappino, A-P., Limacher, J-M., Brons, L., Benhattar, J., Tada, M., Van Meir, E. G., Estreicher, A., and Iggo, R. D. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA, 92: 3963-3967, 1995.
30. Kashiwazaki, H., Tonoki, H., Tada, M., Chiba, I., Shindoh, M., Totsuka, Y., Iggo, R., and Moriuchi, T. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene, 15: 2667-2674, 1997.
31. Waridel, F., Estreicher, A., Bron, L., Flaman, J. M., Fontolliet, C., Monnier, P., Frebourg, T., and Iggo, R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene, 14: 163-169, 1997.
32. Blaszyk, H., Hartmann, A., Tamura, Y., Saitoh, S., Cunningham, J. M., McGovern, R. M., Schroeder, J. J., Schaid, D. J., Li, K., Monden, Y., Morimoto, T., Komaki, K., Sasa, M., Hirata, K., Okazaki, M., Kovach, J. S., and Sommer, S. S. Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations. Oncogene, 13: 2159-2166, 1996.
33. Polyak, K., Waldman, T., He, T. C., Kinzler, K. W., and Vogelstein, B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev., 10: 1945-1952, 1996.
34. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond.), 381: 713-716, 1996.
35. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.
36. Gomez-Manzano, C., Fueyo, J., Kyritsis, A. P., McDonnell, T. J., Steck, P. A., Levin, V. A., and Yung, W. K. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J. Natl. Cancer Inst., 89: 1036-1044, 1997.
37. 1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastomas. Int. J. Radiat. Oncol. Biol. Phys., 36: 95-103, 1996.
38. Malcomson, R. D., Oren, M., Wyllie, A. H., and Harrison, D. J. p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br. J. Cancer, 72: 952-957, 1995.
39. Hermeking, H., Funk, J. O., Reichert, M., Ellwart, J. W., and Eick, D. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/ SDI1. Oncogene, 11: 1409-1415, 1995.
40. Hermeking, H., and Eick, D. Mediation of c-Myc-induced apoptosis by p53. Science (Washington DC), 265: 2091-2093, 1994.